Efficacy and safety of ciprofibrate in hyperlipoproteinaemias

Atherosclerosis. 1996 Jul:124 Suppl:S83-7. doi: 10.1016/0021-9150(96)05861-3.

Abstract

Ciprofibrate is an effective treatment for three main types of atherogenic hyperlipoproteinaemia: type IIa hypercholesterolaemia, type IIb combined hyperlipidaemia, and type IV hypertriglyceridaemia. In type IIa hypercholesterolaemia, administration of 100 mg/day of ciprofibrate, to approximately 3000 patients, decreased total cholesterol (TC), triglycerides, apolipoprotein B (apo B) and low-density lipoprotein (LDL) cholesterol. Levels of apolipoproteins in high-density lipoprotein (HDL) cholesterol and apolipoprotein AI (apo A-I) were increased. Administration of the same dose of ciprofibrate, to approximately 3500 patients with type IIb combined hyperlipidaemia, had a marked cholesterol- and triglyceride-lowering effect, in addition to producing a decrease in LDL cholesterol and apo B, and an increase in apo A-I. TC levels were also decreased in type IV hypertriglyceridaemia following administration of 100 mg/day of ciprofibrate to 800 patients. The decrease in TC levels was attributable to a decrease in triglyceride levels and an increase in HDL cholesterol levels. The pharmacokinetics, mechanism of action and safety of ciprofibrate treatment are also discussed.

Publication types

  • Review

MeSH terms

  • Animals
  • Cardiovascular Diseases / prevention & control
  • Clofibric Acid / adverse effects
  • Clofibric Acid / analogs & derivatives*
  • Clofibric Acid / therapeutic use
  • Fibric Acids
  • Humans
  • Hyperlipoproteinemias / blood
  • Hyperlipoproteinemias / drug therapy*
  • Hypolipidemic Agents / adverse effects
  • Hypolipidemic Agents / therapeutic use*
  • Lipoproteins / blood
  • Lipoproteins / drug effects
  • Safety
  • Treatment Outcome

Substances

  • Fibric Acids
  • Hypolipidemic Agents
  • Lipoproteins
  • Clofibric Acid
  • ciprofibrate